Skip to main content

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie policy for more information on the use of cookies on this website.

Top
  • COVID-19
    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
  • Products
    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers
Home

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers

Main Navigation

  • COVID-19
    Vaccine Development
    Vaccine Development

    Accelerating global operations to manage and process samples critical to vaccine development.

    Azenta Life Sciences Virtual Booth
    Azenta Life Sciences Virtual Booth

    The exhibition experience to your desktop or mobile device

    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
    Resources Center

    Learn about sample management best practices, gain advice from industry leaders, gain access to global regulatory and logistics guidelines and find simple support tools that can help you make better sample management decisions.

    Resources Center
  • Products
    Azenta Sample Pack and Catalog
    Sample Tube Pack Request

    Improve sample tracking, ensure sample integrity and drive process efficiency with Azenta Sample Storage Tubes. Explore the range, and select the best tube for your workflow.

    Low DNA Binding Microplates
    Low Binding Microplates

    Ultra low DNA binding microplates made from PP, fit for Next Generation Sequencing (NGS) and other sensitive applications with ultra-low DNA input. Off the shelf options. Custom solutions on request.

    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    Clinical Trial Management
    Clinical Trial Management

    Life science organizations must collect and manage large numbers of research samples to bring a new therapeutic or diagnostic to market. This is a complex process.

    Sample Preparation & Lab Analytical Services
    Genomics Services by GENEWIZ

    Comprehensive genomics services provide end to end solutions and best-in-class data quality from the trusted experts in genomics.

    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    disaster recovery
    How Safe Are Your Samples?

    Plastic storage tubes are used in laboratories worldwide to store biological and chemical samples.

    Product Support Plans
    Product Support Plans

    Azenta  Life Sciences' world class service team is committed to ensuring you meet your business objectives by providing a flexible portfolio of service products designed to optimize up-time and productivity.

    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    Putting a Sample Kit in an envelope
    Quality Assurance Certifications

    Azenta Life Sciences has established, documented, implemented and currently maintains a quality management system that fulfills the needs of customers.

    About Azenta Life Sciences
    About Azenta Life Sciences

    We are Azenta Life Sciences. We provide unrivaled sample exploration and management solutions to help our customers accelerate discovery, development and delivery.

    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Blog

You are here

  • Home
  • Blog
  • How Will Brexit Affect the Life Science Industry?

How Will Brexit Affect the Life Science Industry?

January 17, 2018

scientist holding petri dishes with red agar

 

Unless the British government does a major about-face, the UK will leave the European Union (EU) on March 30th 2019. This decision is already making itself felt in the British life science community. Life science professionals are worried about how Brexit will affect product development timelines and research collaborations with European partners.

The European Pharmaceutical Review recently published an article by Katheryn Shea, Global Biobanking Lead at Azenta Life Sciences discussing the impact that Brexit will potentially have on the British and European life science industry1.

As Katheryn explained in that article, no Member State has ever left the EU, therefore it is not clear how the regulation and marketing of pharmaceuticals and other life science products will change after Brexit.

However, the European Medicines Agency (EMA), which oversees pharmaceutical regulation in the UK and Europe, has made several statements about how life science companies can continue to comply with regulatory guidelines during the Brexit transition period. In summary:

 

New regulatory rules

The UK will remain part of the EMA during the transition period. This means that until Brexit occurs, the EMA and national regulatory bodies will continue to regulate all pharmaceutical manufacturing, clinical research and marketing authorization of medicines in both the EU and the UK.

After Brexit, the EMA will consider the UK to be a ‘third country’2. Therefore, the UK will be solely responsible for regulating the British life science industry and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK will no longer be involved in regulating drug development and marketing in European countries.

Post-Brexit, there will most likely be one set of regulatory rules for the UK and another for Europe. Any life science researchers sharing reagents or conducting research in both the UK and Europe will have to navigate both sets of guidelines, which could be a source of increased costs and time delays.

The EU and the UK are still negotiating their future trade and regulatory relationships. This means that life science organizations must continue to operate in an uncertain regulatory environment during the transition period.

 

No free trade between the UK and the EU

If the British government cannot negotiate for free trade of pharmaceutical products between the UK and the EU, any active substances or finished medicines manufactured in the UK will have to be imported into the EU, and vice versa. Only authorized importers within the EU or the European Economic Area (EEA) can import products into the EU. All products must comply with EU Good Manufacturing Practice requirements and each batch must be tested at an EU/EEA site of batch control3.

These new regulations will likely add to the cost and time required to move reagents and medicines between the UK and Europe, which is a significant source of concern for life science stakeholders.

 

Managing supply chain issues

In October 2016, the EMA held a stakeholder meeting to better understand the concerns that life science professionals have about Brexit and the transition period.

Manufacturing supply issues was one of the biggest concerns highlighted by life science stakeholders4. Finished pharmaceutical products, active ingredients and biological samples used in research all require temperature-specific and secure shipping and storage conditions. Failure to adhere to these conditions can result in sample degradation and make medicines unfit for sale.

Azenta Life Sciences is actively working with our clients to avoid any cold chain, transport and sample handling issues during the transition period. We have recently opened a best-in-class bioprocessing and biostorage facility near Frankfurt, Germany to accommodate our clients’ growing needs for safe, secure and reliable handling of valuable pharmaceutical and biological samples.

 

What happens next?

Negotiations between the UK and the EU will continue throughout the transition period. The EMA will regularly update regulatory guidelines on its website5. British and European trade organizations and the EMA are conducting industry surveys to identify potential problems caused by Brexit-related regulatory, legal and trading changes.

Brexit means that life science companies will face additional logistical hurdles when storing, transporting and supplying reagents and medicines between the UK and Europe.

Azenta Life Sciences is working hard to make the Brexit transition easier for our clients. We will continue to share any regulatory and legal updates from the EMA and the MHRA to help you plan your research, product development, shipping and marketing both before and after Brexit.

We have also developed a comprehensive suite of solutions to ensure we meet the evolving storage, transport and supply needs of the British and European life science community. Contact us to learn more about how we can help you maintain the integrity of your samples, reagents and medicines throughout the transition period and in the post-Brexit world.

 

References

  1. The impact of Brexit on life sciences. European Pharmaceutical Review. (Online) Available at: https://www.europeanpharmaceuticalreview.com/article/70708/impact-brexit-life-sciences/
  2. Notice to marketing authorisation holders of centrally authorised medicinal products for human and veterinary use. (Online) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/05/WC500226603.pdf (Accessed 23/11/17)
  3. Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to the medicinal products for human and veterinary use within the framework of the Centralised Procedure. (Online) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/05/WC500228739.pdf (Accessed 23/11/17)
  4. Report from Industry Stakeholder Meeting on ‘Brexit’: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/10/WC500237768.pdf
  5. United Kingdom’s withdrawal from the European Union (‘Brexit’). (Online) Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/general/general_content_001707.jsp&mid=WC0b01ac0580a809a7 (Accessed 23/11/17)
  • Sample Storage
  • Biobanking
  • Preclinical & Clinical
Home
Facebook twitter youtube linkedin
Copyright © 2023 Azenta US, Inc.

Footer menu

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Terms of Use
  • Careers
  • Subscribe